Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Dermatol. Feb 2, 2016; 5(1): 52-56
Published online Feb 2, 2016. doi: 10.5314/wjd.v5.i1.52
Treatment of mycosis fungoides, in the era of stem cell transplantation
Pusem Patir, Filiz Vural
Pusem Patir, Filiz Vural, Department of Hematology, Ege University Hospital, Bornova, 35100 Izmir, Turkey
Author contributions: All authors equally contributed to this paper with conception and literature review, and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Filiz Vural, MD, Department of Hematology, Ege University Hospital, Kazimdirik district, Bornova, 35100 Izmir, Turkey.
Telephone: +90-532-5468368 Fax: +90-232-3903530
Received: September 1, 2015
Peer-review started: September 2, 2015
First decision: September 29, 2015
Revised: October 30, 2015
Accepted: December 9, 2015
Article in press: December 11, 2015
Published online: February 2, 2016
Core Tip

Core tip: Some cutaneous T-cell lymphoma patients progress to advanced-stage disease or leukaemic stages. To date, there is no cure for those cases. In the last few years, several publications reported durable responses in some patients following allogeneic hematopoietic stem cell transplantation. Our aim is to define outcomes after hematopoietic stem cell transplantation for mycosis fungoides and Sèzary syndrome.